Increasing evidence indicates that several types of solid tumor are hierarchically organized and sustained by a distinct population of cancer stem cells (CSCs). CSCs possess enhanced mechanisms of protection from stress induced by reactive oxygen species (ROS) that render them resistant to chemo-and radiotherapy. Expression of CD44, especially variant isoforms (CD44v) of this major CSC marker, contributes to ROS defense through upregulation of the synthesis of reduced glutathione (GSH), the primary intracellular antioxidant. CD44v interacts with and stabilizes xCT, a subunit of the cystine-glutamate transporter xc(-), and thereby promotes cystine uptake for GSH synthesis. Given that cancer cells are often exposed to high levels of ROS during tumor progression, the ability to avoid the consequences of such exposure is required for cancer cell survival and propagation in vivo. CSCs, in which defense against ROS is enhanced by CD44v are thus thought to drive tumor growth, chemoresistance and metastasis. Therapy targeted to the CD44v-xCT system may therefore impair the ROS defense ability of CSCs and thereby sensitize them to currently available treatments.
INTRODUCTION
Tumor formation, relapse, and metastasis are thought to be driven by cancer stem cells (CSCs), a subpopulation of cancer cells that give rise to a hierarchical organization of tumors. 1, 2 CSCs are selectively capable of self-renewal and tumor initiation, and they generate the bulk population of nontumorigenic cells in a tumor through differentiation. Given that cancer cells are exposed to environmental stressors such as oxygen or nutrient deficiency, low pH, inflammatory mediators and reactive oxygen species (ROS) in vivo, 3, 4 the ability to avoid the consequences of such exposure is required for the maintenance of CSCs. Furthermore, the efficacy of cancer therapies including radiation therapy and anticancer drugs is attributable in part to the production of ROS and the consequent induction of oxidative stress in cancer cells. 5 CSCs are generally more resistant to oxidative stress provoked by chemo-or radiotherapy compared with non-stem-like cancer cells, however. [6] [7] [8] The targeting of antioxidant systems in CSCs that possess the ability to avoid the adverse consequences of oxidative stress might therefore be expected to improve the efficacy of cancer treatment. This review summarizes current knowledge of the role of variant (v) isoforms of CD44 in redox regulation in cancer cells and in resistance to cancer therapy.
The CSC marker CD44 and its variant isoforms The most widely expressed cell surface markers of CSCs in solid tumors are CD133, CD24, CD44, CD166, CD29 and EpCAM (CD326), with CD44 being the most prevalent of these CSC markers. [9] [10] [11] CD44 is thus highly expressed in CSCs derived from solid tumors including breast, 12 prostate, 13 colon, 14 head and neck 15 and pancreatic 16 cancer.
CD44 is a single-pass type I transmembrane protein and functions as a cellular adhesion molecule for hyaluronic acid, a major component of the extracellular matrix. [17] [18] [19] It exists in numerous isoforms that are generated through alternative splicing of CD44 precursor mRNA. 19 Epithelial splicing regulatory protein 1 (ESRP1) and ESRP2 were recently shown to have a key role in the inclusion of variant exons in the mature forms of CD44 mRNA. 20 Whereas the standard isoform of CD44 (CD44s) is expressed predominantly in hematopoietic cells and normal epithelial cell subsets, CD44v isoforms, which contain additional insertions in the membrane-proximal extracellular region, are highly expressed in epithelial-type carcinomas. Expression of CD44v in some tissues appears to relate to tumor progression, in particular to the metastatic potential of some cancers. [21] [22] [23] [24] Although the functional relevance of CD44 expression in CSCs remains to be established, 11 CD44 is thought to be associated with features of CSCs that are shared with normal stem or progenitor cells, such as interaction with the corresponding niche, 25, 26 the potential for cell migration and homing, [27] [28] [29] the capacity for defense against ROS 30, 31 and resistance to apoptosis. [32] [33] [34] Indeed, RNA interference-mediated depletion of CD44 has revealed that CD44 expression influences the stem-like properties of CSC populations isolated from human breast, 35 prostate 36 and colon 37, 38 cancers, suggesting that CD44 is a potential target for CSC-directed therapy.
Genetic ablation of CD44 in a colon cancer model, the Apc Min mouse, was shown to attenuate the formation of aberrant crypts, implicating CD44 in tumorigenesis. 39 In contrast, genetic ablation of CD44 in a breast cancer model (MMTV-PyVmT mouse) 40 or a gastric cancer model (K19-Wnt1/C2mE mouse) 30 did not reduce the incidence of tumor formation, suggesting that CD44 is not required for onset of tumor formation in these mice. The CD44 dependence of tumor initiation might thus be determined by cellular context.
Although few studies have focused on the role of CD44v in CSCs, it was recently reported that colorectal CSCs express CD44v and that the induction of CD44v expression in these cells was associated with activation of the proto-oncoprotein MET, implicating CD44v in regulation of signaling by MET and its ligand, hepatocyte growth factor. 37 Given that MET promotes the invasive growth of both stem cells and cancer cells, 41 such CD44v-mediated MET activation might also enhance the invasive growth potential of CSCs.
Promotion of the mesenchymal phenotype by CD44s
The epithelial-mesenchymal transition (EMT) is characterized by the loss of epithelial characteristics and the gain of mesenchymal attributes and is a key event in wound healing, tissue repair and several diseases in adults. 42, 43 During the EMT, epithelial cells downregulate cell-cell adhesion systems, lose their polarity, and acquire a mesenchymal phenotype associated with increased interaction with the extracellular matrix as well as an enhanced migratory capacity. 44 Induction of the EMT in several epithelialtype cells was recently found to be accompanied by a shift in CD44 isoforms from CD44v to CD44s that occurs concomitantly with downregulation of ESRP expression. [45] [46] [47] Of note, CD44s has been shown to promote the EMT through the activation of signaling by transforming growth factor b 48, 49 and the protein kinase AKT. 45 Furthermore, CD44s interacts with its major ligand (hyaluronic acid) more effectively than do CD44v isoforms. 50, 51 Together, these observations implicate CD44s, but not CD44v, in the acquisition of mesenchymal properties, including enhanced extracellular matrix interaction and transforming growth factor b signaling, by cancer cells.
Regulation of CD44v by the EMT and hypoxia in cancer cells CD44v is thus highly expressed in epithelial-type carcinomas, and induction of the EMT is associated with a shift in CD44 isoforms from CD44v to CD44s. Experimental induction of the EMT might therefore be expected to elicit an isoform shift from CD44v to CD44s in epithelial cell lines. However, CD44v expression does not always appear to conform to EMT status in cancer cells. We recently found that the expression of CD44 isoforms is not associated with that of EMT markers in 4T1 metastatic mouse breast cancer cells, which include both CD44v þ cells (which predominantly express CD44v) and CD44v À cells (which express only CD44s). 52 Furthermore, chromatin immunoprecipitationsequencing (ChIP-seq) analysis at the ESRP1 gene locus revealed the presence of histone H3 trimethylated at Lys 4 (H3K4me3), a mark of active transcription, at the transcription start site in CD44v þ cells but the presence of H3K27me3, a mark of transcriptional repression, at this site in CD44v À cells, 52 suggesting that CD44v expression is regulated by histone modification at the ESRP1 locus rather than by EMT status in 4T1 cells. Together, these findings suggest that CD44v is not a specific marker for epithelial cancer cells and CD44s is not a specific marker for mesenchymal cancer cells.
Tumor hypoxia has emerged as an important factor in the induction of a pathological EMT leading to cancer progression. [53] [54] [55] Hypoxia and hypoxia-inducible factor-1a were recently shown to stimulate CD44v expression in MDA-MB-231 and SUM-149 breast cancer cells, 56 which exhibit a mesenchymal phenotype. 57 CD44v expression in cancer cells could be thus regulated by EMT independent mechanism. Furthermore, hypoxia signaling promotes the attachment of sialyl Lewis X glycan to CD44v, but not to CD44s, and the modifed CD44v may serve as a ligand for E-selectin expressed in endothelial cells during cancer metastasis. 58, 59 The generation of such glycan-modified CD44v concomitant with the EMT might thus have a role in the promotion of cancer progression by tumor hypoxia.
Modulation of the activity of cell surface proteins by CD44v An emerging concept in signal transduction is that CD44 functions as a co-receptor. 19 A complex of CD44s and a phosphorylated ERM (ezrin/radixin/moesin) protein initiates activation of the transforming growth factor b receptor and the downstream SMAD signaling complex, thereby contributing to acquisition of the mesenchymal phenotype. 49 In addition, several variantspecific domains of CD44 isoforms interact with other cell surface proteins at the plasma membrane ( Figure 1 ). The CD44v3 isoform, (which includes the sequence encoded by variant exon 3) undergoes heparin sulfate modification and interacts with various growth factors, including heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor. 60 Furthermore, such interaction of the pro form of heparin-binding epidermal growth factor-like growth factor with CD44v3 promotes its cleavage by matrix metalloproteinase 7, Figure 1 . Regulation of cell surface proteins by CD44. A complex of CD44s and a phosphorylated ERM (ezrin/radixin/moesin) protein initiates activation of the TGFb receptor (TGFbRII) and the downstream SMAD signaling complex, thereby contributing to acquisition of the mesenchymal phenotype. The CD44v3 isoform interacts with the pro form of heparin-binding epidermal growth factor-like growth factor and thereby promotes its conversion to the active form by MMP7. CD44v6 acts as a co-receptor of the receptor tyrosine kinase MET and thereby promotes signaling by HGF. CD44v3 also interacts with monocarboxylate transporter-1 and monocarboxylate transporter-4, which are responsible for lactate transport, and may thereby contribute to the glycolytic phenotype of cancer cells. CD44v6 and CD44v9 interact with FAS and inhibit programmed cell death induced by FAS ligand (FASL).
yielding the active form of the growth factor that binds to and activates signaling by the receptor tyrosine kinase ERBB4. 61 The CD44v3-mediated activation of heparin-binding epidermal growth factor-like growth factor and its presentation to ERBB4 may therefore contribute to the efficient activation of ERBB4 signaling. The CD44v6 isoform has been shown to act as a co-receptor of the receptor tyrosine kinase MET. 62 CD44v3 also interacts with monocarboxylate transporter-1 and monocarboxylate transporter-4, both of which are responsible for the transport of lactate in breast cancer cells. 63 On the other hand, CD44v6 and CD44v9 interact with the death receptor FAS (CD95) in lipid rafts and thereby interfere with death receptor signaling and inhibit apoptosis. 32 CD44v isoforms may thus serve to modulate the functions of various plasma membrane proteins, including receptor tyrosine kinases, transporters, and a death receptor in cancer cells rather than as mediators of extracellular matrix interaction, with the latter function being subserved primarily by CD44s.
The importance of redox regulation in CSCs Moderate levels of ROS stimulate cell proliferation, whereas high levels that overwhelm the cellular antioxidant capacity trigger cell death. Increased levels of ROS also promote aging of hematopoietic stem cells, 64, 65 whereas high ROS levels in Drosophila sensitize hematopoietic progenitors to the induction of differentiation. 66 The accumulation of ROS in stem cells may thus reduce their self-renewal capability through the activation of aging-or differentiation-related signaling pathways, such as those mediated by p16
INK4a and the retinoblastoma protein 67, 68 or by p38 mitogen-activated protein kinase. 64, 69 Both CSCs of breast cancer and normal mammary stem cells possess an enhanced ROS defense capability compared with their non-stem cell counterparts. 7, 8 Strategies to abrogate ROS defense in CSCs might thus be expected to result in the eradication of these ROS-resistant cells and thereby to provide a basis for the development of efficient cancer therapies.
It is also possible that CSCs are located in a hypoxic microenvironment and therefore show resistance to chemo-or radiotherapy, 6,70 the cytotoxicity of which requires the availability of local oxygen. 71 A more thorough understanding of the CSC niche and elucidation of the mechanisms underlying redox regulation in CSCs may thus lead to improved therapeutic approaches for cancer.
Major sources of ROS in cancer Mitochondrial respiration is a major source of ROS in most mammalian cells. 72, 73 However, most cancer cells metabolize glucose predominantly via aerobic glycolysis and therefore might not rely on mitochondrial respiration for energy production. 74 In such cancer cells, generation of ROS likely results both from increased metabolic activities due to aberrant growth factor and cytokine signaling and to oncogene activation [75] [76] [77] as well as from increased activity of ROS-producing enzymes such as NADPH oxidase, cyclooxygenases and lipoxygenases. 77, 78 In the tumor microenvironment, ROS also can be derived from extrinsic sources. Tumor-infiltrating inflammatory cells such as macrophages and neutrophils generate ROS as a result of NADPH oxidase activation. 78, 79 Cancer therapies including chemo-and radiation therapy also induce ROS generation. 5 Indeed, the mechanism of action of radiotherapy relies primarily on the production of ROS. 71, 80 Given that radiation induces mitotic cell death in dividing cells, 81, 82 most proliferative tumor cells are more sensitive to radiotherapy than quiescent normal cells. Anticancer drugs, including the anthracyclines and platinum coordination complexes, also exert their anticancer effects as well as toxic side effects through ROS generation. 83 Cancer cells that are often exposed to high levels of ROS derived from intrinsic or extrinsic sources thus likely require a wellorganized antioxidant defense system for their survival in vivo (Figure 2 ).
Redox adaptation in cancer cells
Oxidative stress occurs when the production of ROS exceeds the capacity of the cellular defense system, which consists of redox enzymes and other antioxidant molecules. Oncogenic cell proliferation is coupled to the generation of ROS, 68, 84 and cancer cells have therefore evolved mechanisms to protect themselves from oxidative stress and have developed adaptation strategies, including the upregulation of both antioxidants and prosurvival molecules. 5 One consequence of such redox adaptation is that ROS-inducing cancer therapies alone may not be sufficient to damage CSCs, in which the upregulation of antioxidant capacity is especially pronounced.
The adaptation mechanisms include upregulation of redoxsensitive transcription factors, elevation of ROS-scavenging capacity and altered regulation of redox-sensitive death or survival factors. Reduced glutathione (GSH), a ubiquitous reducing thiol peptide that serves as an important intracellular redox buffer, also have a role in redox adaptation in cancer cells. Biosynthesis of GSH is catalyzed by two sequential enzymatic reactions (Figure 3 ). [85] [86] [87] First, glutamate-cysteine ligase, which consists of catalytic glutamate-cysteine ligase and modifier glutamate-cysteine ligase subunits, catalyzes the formation of g-glutamylcysteine from glutamate and cysteine. Glutathione synthetase then couples glycine to g-glutamylcysteine to form GSH. Tumor cells manifest elevated levels of both GSH and GSH metabolic enzymes, which confer resistance to cancer therapies. 88, 89 Natural compounds such as b-phenylethyl isothiocyanate and pipelongumine have recently been shown to influence GSH metabolism and to selectively kill transformed cells without affecting normal cells. 90, 91 The targeting of GSH metabolism may thus effectively disable redox adaptation by cancer cells and thereby damage those cells with active metabolism that leads to the production of high levels of ROS.
The cystine-glutamate antiporter system xc(-) System xc(-) is composed of a light-chain subunit (xCT or SLC7A11) and a heavy-chain subunit (CD98hc or SLC3A2) and functions as a Na þ -independent transporter that mediates the exchange of extracellular cystine (the predominant form of cysteine in plasma, extracellular body fluids and cell culture medium) for intracellular glutamate. [92] [93] [94] The availability of cysteine is rate limiting for GSH synthesis, 95 with the activity of system xc(-) therefore being essential for the GSH-dependent antioxidant system. Mice lacking xCT appear healthy, but they have an increased plasma concentration of cystine compared with their wild-type littermates, 94 suggesting that xCT-mediated cystine transport may be required for cells exposed to severe oxidative stress. Indeed, transcription of the xCT gene is induced by oxidative stress due to electrophilic agents, depletion of cystine, or oxygen, with this effect being mediated through the binding of the transcription factor Nrf2 to its response element in the promoter of the xCT gene. 96 Furthermore, activating transcription factor 4, which has a key role in the response of cells to multiple types of stress, 97 has been shown to upregulate xCT expression. 98, 99 These various observations thus indicate that xCT contributes to the protection of cells exposed to high levels of ROS.
xCT interacts with the type II transmembrane protein CD98hc at the cell surface. 100 Indeed, CD98hc is separately and covalently linked to several light chains that function as amino acid transporters at the plasma membrane, including LAT1, LAT2, y þ LAT1, y þ LAT2, ASC-1 and xCT. 101 The precise mechanism by which CD98hc selects its binding partner to give rise to the Role of CD44v and xc(-) in cancer O Nagano et al different types of functional amino acid transporter has remained unclear, however.
Stabilization of xCT and promotion of cystine uptake by CD44v
Expression of xCT at the surface of cancer cells was found to be modulated by CD44v8-10 (an isoform that includes the sequence encoded by variant exons 8 À 10), which interacts with and thereby stabilizes xCT at the plasma membrane, resulting in promotion of GSH synthesis 30 ( Figure 3 ). RNAi-mediated ablation of CD44v thus reduced the cell surface expression of xCT and thereby depleted intracellular cysteine without affecting the intracellular content of other amino acids. CD44v thus has a key role in the GSH-dependent antioxidant system in cancer cells Figure 2 . Major sources of ROS in cancer. Most cancer cells metabolize glucose predominantly via aerobic glycolysis and therefore might not rely on mitochondrial respiration, which results in ROS production. In such cancer cells, generation of ROS likely results both from increased metabolic activities due to aberrant growth factor and cytokine signaling and to oncogene activation as well as from increased activity of ROS-producing enzymes such as NADPH oxidase, cyclooxygenases and lipoxygenases. In the tumor microenvironment, tumor-infiltrating inflammatory cells such as macrophages and neutrophils release ROS as well as inflammatory cytokines. Cancer therapies including chemoand radiation therapy also induce ROS generation. Figure 3 . Stabilization of xCT and promotion of cystine uptake by CD44v. CD44v contributes to ROS defense by promoting the synthesis of GSH, a primary intracellular antioxidant. CD44v interacts with and stabilizes xCT, a subunit of the cystine-glutamate transporter xc(-), and thereby promotes the uptake of cystine for GSH synthesis. Glutamate-cysteine ligase catalyzes the formation of g-glutamylcysteine from glutamate and cysteine, and glutathione synthetase then couples glycine to g-glutamylcysteine to form GSH.
Role of CD44v and xc(-) in cancer O Nagano et al through modulation of xCT-mediated cystine transport and consequent GSH synthesis. The monitoring of xc(-) transporter activity by positron emission tomography with an 18 F-labeled glutamate derivative was recently shown to be beneficial for the detection of tumors in patients with non-small cell lung cancer or breast cancer. 102 The maximum standardized uptake value for the tracer was found to be significantly correlated with the intensity of immunohistochemical staining for xCT and CD44 in tumor specimens. Although the expression of CD44v specifically was not examined in this study, highly CD44-expressing cancer cells might thus depend on the xc(-) transporter for their survival and propagation in human tumors.
The role of CD44v-xCT in cancer metastasis Cancer metastasis is now thought to result from the dissemination of stem-like cancer cells and their colonization of tissue distant from the primary tumor site. 103 and forced expression of mir-34a in such cells (in which the abundance of this microRNA is reduced compared with that in CD44-negative cells) was found to inhibit metastasis through suppression of CD44 expression. 36 Together, these observations suggest that CD44 þ stem-like cancer cells have an important role in cancer metastasis.
CD44 and its variant isoforms have been implicated in multiple steps required for cancer metastasis, including matrix invasion, extravasation and colonization. 11, 18, 29, 109 Genetic ablation of CD44 in a mouse model of metastatic osteosarcoma (Trp53 þ /tm1 mouse) did not affect the incidence of primary tumor formation, but it did abrogate metastasis, implicating CD44 in metastasis rather than in tumor initiation in this model. 110 On the other hand, genetic ablation of CD44 in the MMTV-PyVmT mouse model of breast cancer enhanced metastatic activity. 40 Furthermore, forced expression of the microRNAs miR-373 and miR-520c, which suppress CD44 expression, was found to confer metastatic activity on MCF-7 breast cancer cells, which normally show a nonmigratory and nonmetastatic phenotype. 111 These observations indicate that CD44 suppresses invasion and metastasis in these breast cancer cells. The dependence of metastasis on CD44 expression thus also seems to be dependent on the cellular context, as appears to be the case for tumorinitiating ability in CSCs. Alternatively, the shift in specific splicing isoform expression rather than a change in baseline CD44 transcription may be associated with those biologic characteristics of CSCs.
In cancer metastasis, the disseminating cells are often exposed to various environmental stressors including ROS. The ability to avoid the consequences of such exposure is therefore required for metastatic CSCs to successfully colonize secondary sites. The redox protein thioredoxin-like 2 was recently shown to regulate the growth and metastasis of human breast cancer cells. Knockdown of redox protein thioredoxin-like 2 in human breast cancer cell lines thus increased ROS levels and thereby reduced the activity of the transcription factor NF-kB, resulting in inhibition of tumor formation and lung metastasis. 112 These results thus also suggested that metastatic growth requires adequate ROS defense ability. Neutrophils were also recently shown to accumulate in the lungs before the arrival of metastatic cells as well as to inhibit lung metastasis of mouse 4T1 metastatic breast cancer cells through NADPH-dependent generation of H 2 O 2 . 113 In the 4T1 mouse model, we recently found that CD44v-expressing lung metastases contain high levels of GSH, but not of its oxidized form glutathione disulfide (glutathione-S-S-glutathione, GSSG), and that CD44v expression enhanced xCT-dependent ROS defense and thereby allowed cancer cells to evade metastatic stress and to colonize the lung. 52 In a mouse model of melanoma metastasis based on B16 melanoma cells, enhanced synthesis of GSH was found to contribute to resistance to oxidative stress and thereby to promote metastatic growth in the liver. 114, 115 Collectively, these observations suggest that neutralization of oxidative stress through the action of the GSH-dependent antioxidant system or other redox proteins at potential sites of metastasis may be required for CSCs to establish metastatic lesions (Figure 4) . Perspective Conventional cancer therapies result in a transient reduction in tumor mass through the killing of non-stem cancer cells. Frequently, however, the cancer reemerges after a few months or even years as a result of the failure to eliminate CSCs. Furthermore, the formation of metastases is thought to result from the dissemination of CSC-like cells and their colonization of secondary sites. Future improvements in cancer treatment may thus require the development of drugs that target signaling or metabolic pathways that are activated specifically in CSC-like cells rather than in non-stem cancer cells, the latter of which are sensitive to currently available treatments.
Redox adaptation by cancer cells contributes to their survival under conditions of persistent oxidative stress due to their intrinsic active metabolism and extrinsic factors in the tumor microenvironment, and it results in resistance to certain anticancer agents. In CSCs, such redox adaptation may be potentiated as a result of their enhanced antioxidant capacity. The targeting of redox regulation in CSCs is thus a candidate approach to CSCdirected therapy. The identification of the main pool of antioxidants that maintains redox status in each type of CSC might lead to the development of efficient therapies for treatment-resistant cancers. In CD44v-expressing CSCs, xCTdependent cystine transport and consequent synthesis of GSH appear to enhance ROS defense and contribute to redox adaptation. Therapy targeted to the CD44v-xCT system may therefore impair ROS defense ability as well as redox adaptation in CSCs and thereby sensitize them to currently available treatments.
